

Deferred registration - Quotient Sciences Code: QSC303684

Submission date 10/07/2026	Recruitment status Not yet recruiting	☒ Prospectively registered ☐ Protocol
Registration date 24/07/2026	Overall study status Deferred	☐ Statistical analysis plan ☐ Results
Last Edited 24/07/2026	Condition category Other	☐ Individual participant data ☒ Record updated in last year

Plain English summary of protocol

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Contact information

Type(s)

Principal investigator

Contact name

Dr Nand Singh

Contact details

Mere Way, Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)3303031000
recruitment@weneedyou.co.uk

Type(s)

Public, Scientific

Contact name

None Clinical Study Director

Contact details

Orionintie 1
Espoo
Finland
FI-0220

+358 (0)10 4261
clinicaltrials@orionpharma.com

Additional identifiers

Integrated Research Application System (IRAS)
1013848

CRO Code
QSC303684

Study information

Scientific Title

Quotient Sciences Code: QSC303684 [Full scientific title to be added on or before the deferral expiry date]

Study objectives

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 21/07/2026, London – Harrow Research Ethics Committee (Health Research Authority 2 Redman Place Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8345; harrow.rec@hra.nhs.uk), ref: 26/LO/0390

Primary study design

Interventional

Allocation

N/A: single arm study

Masking

Open (masking not used)

Control

Uncontrolled

Assignment

Single

Purpose

Phase I trial in healthy volunteers

Study type(s)

Health condition(s) or problem(s) studied

Healthy Volunteers

Interventions

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Primary outcome(s)

1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Key secondary outcome(s)

Completion date

03/10/2026

Eligibility

Key inclusion criteria

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Healthy volunteers allowed

Yes

Age group

Mixed

Lower age limit

30 Years

Upper age limit

65 Years

Sex

Male

Total final enrolment

0

Key exclusion criteria

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Date of first enrolment

27/07/2026

Date of final enrolment

03/10/2026

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre**Quotient Sciences Limited**

Mere Way

Ruddington Fields

Ruddington

Nottingham

England

NG11 6JS

Sponsor information**Organisation**

Orion Corporation (Finland)

ROR

<https://ror.org/0296s4x19>

Funder(s)**Funder type****Funder Name**

Orion Corporation

Alternative Name(s)

Orion, Orion Oyj, OrionPharma - Orion Corporation, OrionPharma, Orion Corporation - Espoo, Finland, orion_finland, Orion Corporation - Pharmaceuticals, Orion (Pharmaceuticals), Orion Corporation (ORNAV.HE)

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

Finland

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not expected to be made available